Geode Capital Management
ENGN icon

Geode Capital Management’s enGene Therapeutics ENGN Stock Holding History

Geode Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,802
Closed -$264K – 4487
2026
Q1 		$264K Buy
38,802
+9,784
+34% +$87.1K ﹤0.01% 3828
2025
Q4 		$262K Hold
29,018
– – ﹤0.01% 3822
2025
Q3 		$198K Hold
29,018
– – ﹤0.01% 3925
2025
Q2 		$106K Hold
29,018
– – ﹤0.01% 4046
2025
Q1 		$130K Hold
29,018
– – ﹤0.01% 3961
2024
Q4 		$193K Buy
29,018
+1,502
+5% +$11.7K ﹤0.01% 3918
2024
Q3 		$182K Hold
27,516
– – ﹤0.01% 3934
2024
Q2 		$259K Buy
27,516
+11,390
+71% +$146K ﹤0.01% 3821
2024
Q1 		$273K Buy
+16,126
New +$197K ﹤0.01% 3832

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Geode Capital Management's ENGN Position: Q2 2026 in Review

Geode Capital Management sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 38,802 shares — an estimated $264K sold.

Geode Capital Management first reported a position in ENGN in Q1 2024 and held it in 9 quarters. The position peaked at $273K in Q1 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Geode Capital Management reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Geode Capital Management sold 38,802 enGene Therapeutics shares in Q2 2026, an estimated $264K.
  • Geode Capital Management first reported a position in enGene Therapeutics in Q1 2024 and held it in 9 quarters.
  • Geode Capital Management's enGene Therapeutics position peaked at $273K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.